A UK research group has been given £2.2 million in funding to seek out additional drugs to treat COVID-19, in case the first wave of therapies fail to show a benefit.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
